drugset / Trial / NCT00053508

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

NCT00053508

Phase 2 Terminated 274 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.

Timeline

Start
2002-09
Primary completion
2003-03
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAM1000 Vaccine 14000 unknown
Subject ACAM1000 Vaccine 70000 unknown
Subject ACAM1000 Vaccine 350000 unknown
Comparator Dryvax Vaccine 250000 unknown

Indications